Thermo Fisher recently opened a new facility in Hangzhou, China to boost biologic and sterile medicine development and add manufacturing capacity in the Asia-Pacific region.
The 80,000-square-foot facility will offer clinical and commercial drug substance and product manufacturing, including capabilities for producing cell lines, biologics and drug substances, and fill-finish abilities. The facility contains a 2,000-liter bioreactor, but in the future, it will eventually have a 5,000-liter bioreactor and a packaging area as well.
Paul Jorjorian In an email to Endpoints News, Paul Jorjorian, the VP and general manager of biologics and pharma services at Thermo Fisher Scientific, said that around 200 jobs will be created with the opening of the Hangzhou site. However, the cost of the facility was not disclosed to Endpoints.
Jorjorian added that the new site is a “strategic addition” to Thermo Fisher’s global network and can address the needs…
Click here to view original post
